Introduction
In a bold and decisive strategic move aimed at reshaping and transforming the landscape of advanced scientific research worldwide, leading artificial intelligence company Anthropic began a gradual rollout and deployment process on Tuesday for its new innovative platform called “Claude Science.” It is a modern workspace and advanced, integrated digital laboratory powered entirely by the latest advanced AI models developed by the company. This comprehensive platform was carefully designed and built with deep thought specifically to provide specialized scientists and researchers with a single, unified, and homogeneous digital workspace that brings together all research tools and covers precise, complex fields such as molecular and cellular biology, organic and fine chemistry, broad genomics, and complex preclinical therapeutic drug discovery and development processes.
This pioneering revolutionary product was officially announced with pride during a live event held in San Francisco, California, under the prominent title “The Briefing: AI for Science.” The event witnessed remarkable attendance and wide-scale participation from senior executives and decision-makers in the global pharmaceutical sector and esteemed scientific research leaders across various research, medical, and academic institutions, reflecting the importance and stature of this launch.
- Direct integration and deep incorporation into daily laboratory workflows
- Building on a solid foundation in the broad life sciences sector
- Massive strategic partnerships with pharmaceutical giants and investors
- Intense and fierce competition in the field of scientific artificial intelligence
- FAQs
Direct integration and deep incorporation into daily laboratory workflows
The launch of the “Claude Science” platform represents Anthropic’s clearest, most direct, and boldest attempt yet to integrate and embed its advanced artificial intelligence models into the core and foundation of the daily, routine workflows of laboratory scientists and researchers, making it an indispensable tool in the lab. In this interconnected context, Inductive Bio, a promising and pioneering tech company specializing in the use of AI to accelerate drug discovery processes, announced on Tuesday that it has officially and fully joined Anthropic’s comprehensive life sciences ecosystem. The company provided a customized and innovative software connector tool that makes Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) prediction models available for direct and seamless use within the Claude platform and Claude Science workspace, strongly and efficiently boosting the integrated platform’s capability to conduct complex drug evaluations and saving scientists years of research and trials.
Building on a solid foundation in the broad life sciences sector
The “Claude Science” platform serves as a natural extension, major development, and logical expansion of Anthropic’s ongoing and intensive research and technical efforts, which kicked off in earnest in October 2025 with the launch of an ambitious initiative and service called “Claude for Life Sciences.” This foundational, early initiative successfully connected the capabilities of Claude’s language models with globally recognized and accredited scientific systems, platforms, and databases such as Benchling (specialized in laboratory notebooks), the National Library of Medicine known as PubMed, and 10x Genomics platform tools, to execute and facilitate complex scientific tasks ranging from the formulation and generation of precise, innovative scientific hypotheses to the drafting and writing of precise, rigorous regulatory, compliance, and medical documents required by health authorities for drug approvals.
This early offering successfully attracted and secured crucial strategic partnerships with giants and massive entities in the field, such as a collaboration with leading company Novo Nordisk to document, write, and analyze complex clinical studies, and with the esteemed Allen Institute for Research and Science to collaborate on the development and design of independent AI agents capable of operating, self-learning, and making decisions in the field of precise biological sciences without continuous human intervention at every step, paving the way for a comprehensive research and laboratory revolution.
Massive strategic partnerships with pharmaceutical giants and investors
In a related development reflecting growing confidence in this advanced platform, Basecamp Research, a strong British biotech company backed and funded directly by prominent investors including the vice chairman of Swiss pharmaceutical giant Roche, confirmed that its foundational models and documents known as “Eden,” precisely dedicated to designing antimicrobial peptides and predicting protein immune responses, are now fully available and integrated for researchers to use through the Claude platform officially and directly. These qualitative additions enhance the platform’s ability to provide comprehensive and advanced solutions. Furthermore, the lineup of esteemed speakers at the massive event clearly highlighted the tremendous scope and significant strategic depth of the company’s ambitions in the pharmaceutical sector, with attendees, presenters, and participants including high-profile and prominent names such as Vas Narasimhan, CEO of Novartis and member of Anthropic’s board of directors, alongside Chris Boerner, CEO of Bristol Myers Squibb.
It is worth noting that Bristol Myers Squibb announced last May, in an excellent proactive move, a massive technical and commercial deal to integrate, deploy, and apply Claude platform technologies across its massive workforce of over 30,000 specialized employees worldwide, for use in advanced basic research, ongoing clinical development, and vital corporate and administrative tasks to increase productivity and reduce human error margins when handling sensitive medical data.
Intense and fierce competition in the field of scientific artificial intelligence
This powerful, influential, and interesting announcement comes at a time when competition is intensifying and the technological space of AI-powered scientific workspaces and platforms is witnessing a noticeable rise in rivalry between giant and innovative tech companies. Just one day prior to Anthropic’s official announcement, leading companies Databricks and Nvidia launched their joint and competing platform called “Genesis Workbench,” which also explicitly targets the demographic of medical AI scientists and researchers to provide innovative solutions, pointing to a frantic race to control this promising strategic sector. Anthropic had already marketed its advanced “Fable 5” model, released earlier in June, for use in complex applications related to new drug discovery and development, claiming in its technical papers and ambitious announcements that this model actively accelerated various aspects and specific stages of complex drug design processes by nearly 10 times the speed compared to traditional methods—a figure considered a true revolution in this difficult and complex field.
The company’s special event and showcase, which featured live and impressive product and tool demonstrations during its main program running from 10:00 AM to 11:40 AM Pacific Daylight Time, featured important and in-depth panel discussions and sessions presented and attended by prominent experts and scientific figures in this vital sector. Among these experts were Aviv Regev, head of early research and development at Genentech, and Eric Coudrier Abrams, head of life sciences at Anthropic, reaffirming the company’s deep commitment to building a strong and integrated scientific community around its technology platform.
FAQs
Question: What is the Claude Science platform launched recently?
Answer: It is an integrated AI-powered workspace and digital hub dedicated to scientists to facilitate complex research in biology, genomics, and drug discovery by integrating computing tools into a single interface.
Question: How will Inductive Bio contribute to supporting the capabilities of this platform?
Answer: The company will provide a tool to connect the Claude Science platform with its ADMET prediction models and technology, enhancing scientists’ ability to conduct complex drug evaluations for toxicity and absorption smoothly and rapidly.
Question: What is the scale of Claude platform adoption at Bristol Myers Squibb?
Answer: Bristol Myers Squibb signed an agreement to integrate and provide Claude platform technologies and tools to over 30,000 employees working in research, development, and administrative departments to increase work efficiency.
Question: Does Anthropic face competition in this specialized field?
Answer: Yes, absolutely. It faces fierce and direct competition from tech giants, as Databricks and Nvidia have launched the competing Genesis Workbench platform targeted at the exact same demographic of scientists and researchers.
